T
AXSM icon

Transce3nd’s Axsome Therapeutics AXSM Stock Holding History

Transce3nd’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-209
Closed -$21.8K – 229
2025
Q2 		$21.8K Buy
209
+59
+39% +$6.25K 0.01% 431
2025
Q1 		$17.5K Buy
150
+16
+12% +$1.82K 0.01% 461
2024
Q4 		$11.3K Buy
+134
New +$12.3K ﹤0.01% 717

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Transce3nd's AXSM Position: Q3 2025 in Review

Transce3nd sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 209 shares — an estimated $21.8K sold.

Transce3nd first reported a position in AXSM in Q4 2024 and held it in 3 quarters. The position peaked at $21.8K in Q2 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Transce3nd reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 209 Axsome Therapeutics shares in Q3 2025, an estimated $21.8K.
  • Transce3nd first reported a position in Axsome Therapeutics in Q4 2024 and held it in 3 quarters.
  • Transce3nd's Axsome Therapeutics position peaked at $21.8K in Q2 2025.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.